Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia
- PMID: 20169624
- PMCID: PMC2946382
- DOI: 10.1002/hep.23515
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia
Abstract
Studies of human leukocyte antigen (HLA) alleles and their relation with hepatitis C virus (HCV) viremia have had conflicting results. However, these studies have varied in size and methods, and few large studies assessed HLA class I alleles. Only one study conducted high-resolution class I genotyping. The current investigation therefore involved high-resolution HLA class I and II genotyping of a large multiracial cohort of U.S. women with a high prevalence of HCV and HIV. Our primary analyses evaluated associations between 12 HLA alleles identified through a critical review of the literature and HCV viremia in 758 HCV-seropositive women. Other alleles with >5% prevalence were also assessed; previously unreported associations were corrected for multiple comparisons. DRB1*0101 (prevalence ratio [PR] = 1.7; 95% confidence interval [CI] = 1.1-2.6), B*5701 (PR=2.0; 95% CI = 1.0-3.1), B*5703 (PR = 1.7; 95% CI = 1.0-2.5), and Cw*0102 (PR = 1.9; 95% CI = 1.0-3.0) were associated with the absence of HCV RNA (i.e., HCV clearance), whereas DRB1*0301 (PR = 0.4; 95% CI = 0.2-0.7) was associated with HCV RNA positivity. DQB1*0301 was also associated with the absence of HCV RNA but only among HIV-seronegative women (PR = 3.4; 95% CI = 1.2-11.8). Each of these associations was among those predicted. We additionally studied the relation of HLA alleles with HCV infection (serostatus) in women at high risk of HCV from injection drug use (N = 838), but no significant relationships were observed.
Conclusion: HLA genotype influences the host capacity to clear HCV viremia. The specific HLA associations observed in the current study are unlikely to be due to chance because they were a priori hypothesized.
Conflict of interest statement
Dr. Terrault has received research grants from Roche, Vertex, and Human Genome Sciences. All other authors, no conflicts.
Similar articles
-
Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA class I and class II.Viral Immunol. 2007 Summer;20(2):312-9. doi: 10.1089/vim.2006.0060. Viral Immunol. 2007. PMID: 17603847
-
Effect of human leukocyte antigen class I and II alleles on hepatitis C viral load among chronic hepatitis C patients in Southern Taiwan.Hum Immunol. 2013 Aug;74(8):978-82. doi: 10.1016/j.humimm.2013.04.023. Epub 2013 Apr 27. Hum Immunol. 2013. PMID: 23628398
-
Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population.Hepatology. 2000 Jun;31(6):1334-7. doi: 10.1053/jhep.2000.7437. Hepatology. 2000. PMID: 10827160
-
A comparative review of HLA associations with hepatitis B and C viral infections across global populations.World J Gastroenterol. 2007 Mar 28;13(12):1770-87. doi: 10.3748/wjg.v13.i12.1770. World J Gastroenterol. 2007. PMID: 17465466 Free PMC article. Review.
-
Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome.Mol Immunol. 2008 May;45(9):2429-36. doi: 10.1016/j.molimm.2008.01.002. Epub 2008 Mar 4. Mol Immunol. 2008. PMID: 18289678 Free PMC article. Review.
Cited by
-
Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up.Viruses. 2021 Aug 12;13(8):1596. doi: 10.3390/v13081596. Viruses. 2021. PMID: 34452460 Free PMC article. Review.
-
Super high-resolution single-molecule sequence-based typing of HLA class I alleles in HIV-1 infected individuals in Ghana.PLoS One. 2022 Jun 2;17(6):e0269390. doi: 10.1371/journal.pone.0269390. eCollection 2022. PLoS One. 2022. PMID: 35653364 Free PMC article.
-
Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).PLoS One. 2015 Aug 4;10(8):e0134158. doi: 10.1371/journal.pone.0134158. eCollection 2015. PLoS One. 2015. PMID: 26241854 Free PMC article.
-
Effect of HLA on hepatitis C virus clearance and persistence in anti-HCV-positive end-stage renal disease patients.Saudi J Gastroenterol. 2014 May-Jun;20(3):175-81. doi: 10.4103/1319-3767.133007. Saudi J Gastroenterol. 2014. PMID: 24976281 Free PMC article.
-
Understanding the genetic determinant of severity in viral diseases: a case of SARS-Cov-2 infection.Egypt J Med Hum Genet. 2020;21(1):77. doi: 10.1186/s43042-020-00122-z. Epub 2020 Dec 31. Egypt J Med Hum Genet. 2020. PMID: 38624552 Free PMC article. Review.
References
-
- Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714. - PubMed
-
- Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 (Suppl 1):74–81. - PubMed
-
- Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, et al. Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis. 2008;198:1749–1755. - PubMed
-
- Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383–98. vi. - PubMed
-
- Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–1233. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UO1-HD-32632/HD/NICHD NIH HHS/United States
- U01 DK066116/DK/NIDDK NIH HHS/United States
- UO1-AI-34989/AI/NIAID NIH HHS/United States
- U01 AI031834/AI/NIAID NIH HHS/United States
- R56 AI052065/AI/NIAID NIH HHS/United States
- U01 AI035004/AI/NIAID NIH HHS/United States
- R01 AI057006/AI/NIAID NIH HHS/United States
- UO1-AI-35004/AI/NIAID NIH HHS/United States
- UO1-AI-34993/AI/NIAID NIH HHS/United States
- U01 AI034994/AI/NIAID NIH HHS/United States
- 5R01AI057006-04/AI/NIAID NIH HHS/United States
- UO1-AI-42590/AI/NIAID NIH HHS/United States
- UO1-AI-31834/AI/NIAID NIH HHS/United States
- HHSN261200800001E/CA/NCI NIH HHS/United States
- UO1-AI-34994/AI/NIAID NIH HHS/United States
- R01A1052065/PHS HHS/United States
- UL1 RR024131/RR/NCRR NIH HHS/United States
- U01 AI034989/AI/NIAID NIH HHS/United States
- R01 AI052065/AI/NIAID NIH HHS/United States
- R01AI057006/AI/NIAID NIH HHS/United States
- L30 AI084473/AI/NIAID NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- HHSN261200800001C/RC/CCR NIH HHS/United States
- U01 AI034993/AI/NIAID NIH HHS/United States
- U01 HD032632/HD/NICHD NIH HHS/United States
- U01 AI042590/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials